[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527157":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":53,"studyPopulation":43,"armGroups":54,"interventions":67,"overallOfficials":43,"centralContacts":77,"locations":83,"responsibleParty":99,"collaborators":102,"id":104,"slug":43,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":43,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":43,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":129,"whyStopped":43,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Konkuk University Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":43},[9],{"measure":10,"description":11,"timeFrame":12},"intergroup difference in the treatment time (T-time)","The treatment time (T-time): the duration from ordering cryoprecipitate or FC to completing its administration","1 min",[14,18,21,24,27,30,33,37,40],{"measure":15,"description":16,"timeFrame":17},"Red Blood Cell amount","Red Blood Cell transfusion amount during surgery","1 hour",{"measure":19,"description":20,"timeFrame":17},"FFP amount","FFP transfusion amount during surgery",{"measure":22,"description":23,"timeFrame":17},"Platelet amount","Platelet transfusion amount during surgery",{"measure":25,"description":26,"timeFrame":12},"r-time","CK r-time after PCC or FFP",{"measure":28,"description":29,"timeFrame":12},"CRT-MA","CRT-MA after PCC or FFP",{"measure":31,"description":32,"timeFrame":12},"CFF-MA","CFF-MA after PCC or FFP",{"measure":34,"description":35,"timeFrame":36},"Bleeding","Postoperative bleeding amount","6 hour",{"measure":38,"description":39,"timeFrame":17},"oxygenation profile","PaO2\u002FFiO2 ratio",{"measure":41,"description":42,"timeFrame":12},"preparation time of cryoprecipitate or FC","time from the start of preparation (ABO-cross matching and thawing of cryoprecipitate or unpacking FC from its storage) to the delivery to patients in the operation theater",null,{"allocation":45,"interventionModel":46,"interventionModelDescription":43,"primaryPurpose":47,"observationalModel":43,"timePerspective":43,"maskingInfo":48},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":49,"maskingDescription":43,"whoMasked":50},"DOUBLE",[51,52],"PARTICIPANT","OUTCOMES_ASSESSOR","The primary outcome is an inter-group comparison of treatment time (T-time, the duration from ordering cryoprecipitate or FC to completing its administration). The secondary measures include comparisons of perioperative bleeding, blood transfusion, coagulation profiles, reoperation, thromboembolic complications, mortality, oxygenation profiles, fibrinolysis phenotypes, and costs for bleeding management and length of hospital stay.",[55,61],{"label":56,"type":57,"description":58,"interventionNames":59},"cryoprecipitate","ACTIVE_COMPARATOR","If serum-fibrinogen \\\u003C 100 mg\u002Fdl or CFF-MA \\\u003C 15 mm in thromboelastography (TEG), cryoprecipitate is administered",[60],"Biological: fresh frozen plasma",{"label":62,"type":63,"description":64,"interventionNames":65},"fibirnogen concentrate","EXPERIMENTAL","If serum-fibrinogen \\\u003C 80 mg\u002Fdl or CFF-MA \\\u003C 15 mm in thromboelastography (TEG), fibrinogen concentrate is administered.",[66],"Biological: prothrombin complex concentrate",[68,73],{"type":69,"name":70,"description":71,"armGroupLabels":72,"otherNames":43},"BIOLOGICAL","fresh frozen plasma","transfusion of fresh frozen plasma",[56],{"type":69,"name":74,"description":75,"armGroupLabels":76,"otherNames":43},"prothrombin complex concentrate","prothrombin complex concentrate administration",[62],[78],{"name":79,"role":80,"phone":81,"phoneExt":43,"email":82},"Tae-Yop Kim, MD PhD","CONTACT","+82-10-8811-6942","taeyop@gmail.com",[84],{"facility":85,"status":43,"city":86,"state":43,"zip":43,"country":87,"countryCode":43,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Samsung Medical Center","Seoul","South Korea",{"type":89,"coordinates":90},"Point",[91,92],126.9784,37.566,{"lat":92,"lon":91},[95],{"name":96,"role":80,"phone":97,"phoneExt":43,"email":98},"Yu Jeong Bang, MD, PhD","+821051758275","gagreflex.bang@gmail.com",{"type":100,"investigatorFullName":79,"investigatorTitle":101,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"PRINCIPAL_INVESTIGATOR","Professor of Anesthesiology",[103],{"name":85,"class":6},"100527157",false,"NCT06144112","Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery","A Randomized Trial Comparing the Time for Managing Intraoperative Hypofibrinogenemia Using Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery (FIBCRYO-LT Trial)","Inclusion Criteria:\n\n* Liver disease undergoing Liver transplantation\n\nExclusion Criteria:\n\n\\-",true,"ALL","20 Years","75 Years",{"count":115,"type":116},92,"ESTIMATED","INTERVENTIONAL",[119],"PHASE4","We compared the time consumed for goal-directed management of hypofibrinogemia using two strategies during liver transplant (LT) surgery: a conventional cryoprecipitate-based strategy versus a lyophilized fibrinogen concentrate-based strategy",[122],"Liver Diseases",[124,125,126,56,127,128],"hypofirinogenemia","coagulopathy","fibrinogen","liver transplantation","lyophilized factor concentrates","NOT_YET_RECRUITING","2025-07-16",{"date":132,"type":133},"2025-07-20","ACTUAL",{"date":135,"type":116},"2025-09-01",{"date":137,"type":116},"2026-03-31",{"name":5,"class":6},1]